pharmaphorum Editor

Views & Analysis

Nine for 2019: Challenges impacting pharma

As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.

ASCO 2019 and the future of oncology

ASCO 2019 – phase I data generates hope for the future

Sometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. One such story at ASCO 2019 was the data on Amgen’s KRAS

Views & Analysis

Nine for 2019 Challenges impacting pharma

Nine for 2019: Opportunities for pharma

In the last Nine for 2019 article, we reflected on the major challenges that are sha

ASCO 2019 and the future of oncology

ASCO 2019 - Kantar considers MacroGenics' phase 3 SOPHIA tri...

Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last day of ASCO 2019. MacroGenics' trial compared its margetuximab candida